Free tool
FAERS Monitor: Ziac
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020186 or its brand name (Ziac, Bisoprolol Fumarate, Hydrochlorothiazide). Reports on generic versions are filed under their own applications.
Reports
620
Serious
443
71% of reports
Hospitalization
263
Death reported
54
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache50
- fatigue44
- drug ineffective43
- nausea42
- pruritus39
- pain38
- hypertension37
- vomiting36
- diarrhoea33
- rash33
- dyspnoea32
- arthralgia31
- hypersensitivity31
- off label use30
- dizziness29
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 39 |
| 2006 | 18 |
| 2007 | 33 |
| 2008 | 41 |
| 2009 | 42 |
| 2010 | 75 |
| 2011 | 64 |
| 2012 | 95 |
| 2013 | 5 |
| 2014 | 7 |
| 2015 | 12 |
| 2016 | 20 |
| 2017 | 19 |
| 2018 | 24 |
| 2019 | 14 |
| 2020 | 12 |
| 2021 | 15 |
| 2022 | 15 |
| 2023 | 8 |
| 2024 | 14 |
| 2025 | 14 |
| 2026 | 12 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,539 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypertensionSignal | 37 | 5.9 | 4.3 | 148 |
| hypersensitivitySignal | 31 | 5.7 | 4.0 | 116 |
| pruritusSignal | 39 | 3.4 | 2.5 | 66 |
| headacheSignal | 50 | 2.7 | 2.1 | 54 |
| vomitingSignal | 36 | 2.6 | 1.9 | 35 |
| rashSignal | 33 | 2.6 | 1.8 | 31 |
| arthralgiaSignal | 31 | 2.5 | 1.8 | 28 |
| painSignal | 38 | 2.1 | 1.5 | 21 |
| dizziness | 29 | 2.0 | 1.4 | 13 |
| dyspnoea | 32 | 1.9 | 1.4 | 14 |
| fatigue | 44 | 1.9 | 1.4 | 19 |
| nausea | 42 | 1.8 | 1.3 | 15 |
| diarrhoea | 33 | 1.7 | 1.2 | 10 |
| off label use | 30 | 1.2 | 0.8 | 1 |
| drug ineffective | 43 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.